Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: Beginning of epidemic control

Vaccine

Volumn 24, Issue 9, 2006, Pages 1395-1400

  Thornton, V ^a   Lennon, D ^a   Rasanathan, K ^a   O'Hallahan, J ^c   Oster, P ^d   Stewart, J ^a   Tilman, S ^d   Aaberge, I ^e   Feiring, B ^e   Nokleby, H ^e   Rosenqvist, E ^e   White, K ^a   Reid, S ^f   Mulholland, K ^g   Wakefield, M J ^d   Martin, D ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

^c MINISTRY OF HEALTH   (New Zealand)

^d CHIRON VACCINES   (Italy)

^e NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^f Ropata Medical Centre   (New Zealand)

^g UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Meningococcal group B; OMV vaccine; Phase I II trial

Indexed keywords

BACTERIUM ANTIBODY; MENINGOCOCCUS VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ARTHRALGIA; ARTICLE; BACTERIAL STRAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EPIDEMIC; ERYTHEMA; FEMALE; HUMAN; IMMUNOGENICITY; INFECTION CONTROL; INJECTION SITE PAIN; MALAISE; MALE; MEMBRANE VESICLE; MENINGOCOCCOSIS; MYALGIA; NAUSEA; NEISSERIA MENINGITIDIS; NEW ZEALAND; NORMAL HUMAN; OUTER MEMBRANE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SKIN INDURATION; SWELLING; VACCINATION; VACCINATION REACTION;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; HUMAN EXPERIMENTATION; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MIDDLE AGED; NEW ZEALAND; SINGLE-BLIND METHOD; SPECIES SPECIFICITY;

EID: 32344436176     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.09.043     Document Type: Article

References (26)

1. D.R. Martin, S.J. Walker, M.G. Baker, and D.R. Lennon New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4 J Infect Dis 177 1998 497 500
2. Ministry of Health. The epidemiology of meningococcal disease in New Zealand in 2002 (http://www.moh.govt.nz).
3. C. Bremner, D. Lennon, D. Martin, M. Baker, and H. Rumke Epidemic meningococcal disease in New Zealand: epidemiology and potential for prevention by vaccine N Z Med J 112 1091 1999 257 259
4. G.V.G. Sierra, H.C. Campa, N.M. Varcacel, I.L. Sarcia, P.L. Izqierdo, and P.F. Sotolongo Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba NIPH Ann 14 2 1991 195 207
5. G. Bjune, E.A. Hoiby, J.K. Gronnesby, O. Arnesen, J.H. Fredriksen, and A.K. Lindbak Effect of an outer membrane vesicle vaccine against group B meningococcal disease in Norway Lancet 338 1991 1093 1096
6. J.D. Wenger Serogroup B meningococcal disease: new outbreaks, new strategies JAMA 281 16 1999 1541 1543
7. J.W. Tappero, R. Lagos, A.M. Ballesteros, B. Pikaytis, D. Williams, and J. Dykes Immunogenicity of 2 Serogroup B outer-membrane protein meningococcal vaccines: a randomised controlled trial in chile JAMA 281 16 1999 1520 1527
8. J. Holst, B. Feiring, L. Meyer Naess, G. Norheim, P. Kristiansen, and E.A. Hoiby The concept of "tailor-made", protein based outer membrane vesicle vaccines against meningococcal disease Vaccine 23 2005 2202 2205
9. E. Miller, D. Salisbury, and M. Ramsay Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story Vaccine 20 Suppl. 1 2002 S58 S67
10. I. Goldschneider, E. Gotschlich, and M. Artenstein Human immunity to the meningococcus. I The role of humoral antibodies J Exp Med 129 1969 1307 1326
11. I. Goldschneider, E. Gotschlich, and M. Artenstein Human immunity to the meningococcus. II Development of natural immunity J Exp Med 129 1969 1327 1348
12. E. Gotschlich, I. Goldschneider, and M. Artenstein Human immunity to the meningococcus. IV Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers J Exp Med 129 1969 1367 1384
13. J. Boslego, J. Garcia, C. Cruz, W. Zollinger, B. Brandt, and M. Martinez Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile Vaccine 13 9 1995 821 829
14. E.A. Hoiby, E. Rosenqvist, L.O. Froholm, G. Bjune, B. Feiring, and H. Nokleby Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey NIPH Ann 14 2 1991 147 155 (discussion 155-6)
15. E. Rosenqvist, E.A. Hoiby, E. Wedege, B. Kusecek, and M. Achtman The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies J Infect Dis 167 1993 1065 1073
16. L.C. Milagres, S.R. Ramos, C.T. Saachi, C.E.A. Melles, V.S.D. Vieira, and H. Sato Immune response of brazilian children to a neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy Infect Immun 62 10 1994 4419 4424
17. A. Aase, G. Bjune, E.A. Hoiby, E. Rosenqvist, A.K. Pedersen, and T.E. Michaelsen Comparison among opsonic activity, antimeningococcal immunoglobulin g response, and serum bactericidal activity against meningococci in sera from vaccines after immunization with a serogroup b outer membrane vesicle vaccine Infect Immun 63 9 1995 3531 3536
18. E. Rosenqvist, E.A. Hoiby, E. Wedege, K. Bryn, J. Kolber, and A. Klem Human antibody responses to meningococcal outer membrane antigens after three doses of the norwegian group B meningococcal vaccine Infect Immun 63 12 1995 4642 4652
19. C.C.A.M. Peeters, H.C. Rumke, L.C. Sundermann, E.R. Van der Voort, J. Meulenbelt, and M. Schuller Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine Vaccine 14 10 1996 1009 1015
20. E.R. Van der Voort, P. Van der Ley, J. Van der Biezen, S. George, O. Tunnela, and H. Van Dijken Specificity of human bactericidal antibodies against porA P1.7, 16 induced with a hexavalent meningococcal outer membrane vesicle vaccine Infect Immun 64 1996 2745 2751
21. B.A. Perkins, K. Jonsdottir, H. Briem, E. Griffiths, B.D. Pikaytis, and E. Hoiby Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland J Infect Dis 177 1998 683 691
22. J. Holst, B. Feiring, J.E. Fuglesang, E. Hoiby, H. Nokleby, and I. Aaberge Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease Vaccine 21 7-8 2003 734 737
23. C.E. Frasch, L. van Alphen, J. Holst, J.T. Poolman, and E. Rosenqvist Outer membrane protein vesicle vaccines for meningococcal disease A.J. Pollard M.C.J. Maiden Methods in molecular medicine meningococcal vaccines: methods and protocols vol. 66 2001 Humana Press Inc. Totowa, New Jersey 81 107
24. Rosenqvist E, Bryn K, Harbak K, Holst J, Hoiby E, Kristiansen P. Development of a tailor-made outer membrane vesicle vaccine against the group B meningococcal epidemic in New Zealand. In: Abstracts of the 13th international pathogenic neisseria conference. AS, Oslo: Nordberg Aksidenstrykkeri; 2002. p. 64.
25. H. Nokleby, and B. Feiring The Norwegian meningococcal group B outer membrane vesicle vaccine: side effects in phase II trials NIPH Ann 14 2 1991 95 101 (discussion 101-2)
26. M. Fischer, G.M. Carlone, J. Holst, D. Williams, D.S. Stephens, and B.A. Perkins Neisseria meningitidis serogroup B outer membrane vesicle vaccine in adults with occupational risk for meningococcal disease Vaccine 17 19 1999 2377 2383